We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
-5.89%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.55B
AUM Growth
–
Cap. Flow
+$1.69B
Cap. Flow %
108.72%
Top 10 Hldgs %
99.28%
Holding
16
New
16
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$581M
2
RCUS icon
Arcus Biosciences
RCUS
+$491M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$466M
4
ASMB icon
Assembly Biosciences
ASMB
+$35.6M
5
TNGX icon
Tango Therapeutics
TNGX
+$22.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Financials 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$515M 33.23%
+6,720,803
New +$581M
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$462M 29.77%
+16,707,477
New +$466M
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$448M 28.86%
+30,061,124
New +$491M
ASMB icon
4
Assembly Biosciences
ASMB
$498M
$34.9M 2.25%
+2,209,471
New +$35.6M
MRUS
5
DELISTED
Merus
MRUS
$19M 1.23%
+452,527
New +$21.7M
KYTX icon
6
Kyverna Therapeutics
KYTX
$444M
$15.4M 0.99%
+4,126,119
New +$19.8M
CYPH
7
Cypherpunk Technologies Inc
CYPH
$62.9M
$15.3M 0.99%
+5,319,148
New +$15.8M
TNGX icon
8
Tango Therapeutics
TNGX
$4.43B
$15M 0.97%
+4,854,443
New +$22.5M
XLO icon
9
Xilio Therapeutics
XLO
$59.9M
$8.7M 0.56%
+650,389
New +$8.95M
KLRS
10
Kalaris Therapeutics
KLRS
$83.5M
$6.99M 0.45%
+723,273
New +$10.9M
HOOK
11
DELISTED
HOOKIPA Pharma
HOOK
$3.77M 0.24%
+1,875,945
New +$5.8M
IMA
12
ImageneBio Inc
IMA
$63M
$3.29M 0.21%
+167,362
New +$3.38M
ALLO icon
13
Allogene Therapeutics
ALLO
$649M
$2.46M 0.16%
+1,156,689
New +$2.85M
BRNS
14
Barinthus Biotherapeutics
BRNS
$22.8M
$749K 0.05%
+620,351
New +$722K
AGEN
15
Agenus
AGEN
$312M
$635K 0.04%
+231,663
New +$858K
KRON
16
DELISTED
Kronos Bio
KRON
$179K 0.01%
+188,567
New +$178K

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Gilead Sciences's Q4 2024 Portfolio in Review

Q4 2024 is the first quarter with a 13F filing on record for Gilead Sciences, which disclosed 16 positions worth $1.55B. Its ten largest holdings account for 99% of the portfolio.

Its largest position is Arcellx: 6,720,803 shares worth $515M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Financials.

  • Gilead Sciences's largest Q4 2024 buy was Arcellx: 6,720,803 shares worth $515M.
  • Gilead Sciences's ten largest holdings make up 99% of its $1.55B portfolio in Q4 2024.
  • Gilead Sciences disclosed 16 positions in Q4 2024, its first 13F filing on record.

Based on Gilead Sciences's 13F filing for Q4 2024, filed 13 Feb 2025.